Skip to main content
SpringerLink
Log in

Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant Rejection

  • Review Articles
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Mycophenolate mofetil (the morpholinoethyl ester of mycophenolic acid) inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase. Its selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation. Mycophenolate mofetil has immunosuppressive effects alone, but is used most commonly in combination with other immunosuppressants. Mycophenolate mofetil, in combination with cyclosporin and corticosteroids, has been studied in large, randomised clinical trials involving nearly 1500 renal allograft transplant recipients. These trials demonstrated that mycophenolate mofetil is significantly more effective in reducing treatment failure and acute rejection episodes than placebo or azathioprine. Additionally, mycophenolate mofetil may be able to reduce the occurrence of chronic rejection.

Mycophenolate mofetil is relatively well tolerated. The most common adverse effect reported is gastrointestinal intolerance; haematological aberrations have also been noted. The reversible cytostatic action of mycophenolate mofetil allows for dose adjustment or discontinuation, preventing serious toxicity or an overly suppressed immune system. Cytomegalovirus tissue invasive disease and the development of malignancies are concerns that merit evaluation in long term follow-up studies.

Mycophenolate mofetil does not cause the adverse effects typically associated with other commercially available immunosuppressant medications such as nephrotoxicity, hepatotoxicity, hypertension, nervous system disturbances, electrolyte abnormalities, skin disorders, hyperglycaemia, hyperuricaemia, hypercholesterolaemia, lipid disorders and structural bone loss.

Based on preliminary information, a positive benefit-risk ratio has been demonstrated with the use of mycophenolate mofetil in the prophylaxis of rejection in cadaveric renal allograft transplantation. Data from studies in other types of organ transplants are promising, but are too limited to draw clear conclusions. Long term follow-up studies are required to confirm these observations. Although mycophenolate mofetil is expensive, the beneficial effects on the reduction of rejection, treatment failure and related expenses suggest that it is most likely to be cost effective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Halloran PF. Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Transplant Proc 1996 Dec; 28 (6) 1 Suppl.: 11–8

    PubMed  CAS  Google Scholar 

  2. Florey HW, Gilliver K, Jennings MA, et al. Mycophenolic acid — an antibiotic from Penicillium brevicompactum. Lancet 1946; I: 46–9

    Article  Google Scholar 

  3. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through aminoester derivatization. Pharm Res 1990 Feb; 7 (2): 161–6

    Article  PubMed  CAS  Google Scholar 

  4. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969 Aug 23; 223 (208): 848–50

    Article  PubMed  CAS  Google Scholar 

  5. Williams RH, Lively DH, Delong DC, et al. Mycophenolic acid: antiviral and antitumor properties. J Antibiot 1968 Jul; 21 (7): 463–4

    Article  PubMed  CAS  Google Scholar 

  6. Lynch WS, Roenigk Jr HH. Mycophenolic acid for psoriasis. Arch Dermatol 1977 Sep; 113 (9): 1203–8

    Article  PubMed  CAS  Google Scholar 

  7. Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis: a review of pharmacology, long term efficacy, and safety. J Am Acad Dermatol 1987 Dec; 17 (6): 962–71

    Article  PubMed  CAS  Google Scholar 

  8. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11 (8 Suppl.): 117–9S

    Google Scholar 

  9. Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993; 696: 63–87

    Article  PubMed  CAS  Google Scholar 

  10. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969 Jul; 113 (3): 515–24

    PubMed  CAS  Google Scholar 

  11. Verham R, Meek TD, Hedstrom L, et al. Purification, characterization, and kinetic analysis of inosine 5′-monophosphate dehydrogenase of trichomonas foetus. Mol Biochem Parasitol 1987 May; 24(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  12. Morris RE, Hoyt EG, Eugui EM, et al. Prolongation of rat heart allograft survival of RS61443. Surg Forum 1989; 40: 337–8

    Google Scholar 

  13. Platz KP, Sollinger HW, Hullett DA, et al. RS-61443: a new, potent immunosuppressive agent. Transplantation 1991 Jan; 51 (1): 27–31

    Article  PubMed  CAS  Google Scholar 

  14. Benhaim P, Anthony JP, Lin LY, et al. A long term study of allogeneic rat hind limb transplants immunosuppressed with RS-61443. Transplantation 1993 Oct; 56 (4): 911–7

    Article  PubMed  CAS  Google Scholar 

  15. O’Hair DP, McManus RA, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994 Nov; 58(5): 1311–5

    Article  PubMed  Google Scholar 

  16. Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): mechanisms of action and effects in transplantation. Transplant Rev 1993 Jul; 7 (3): 129–39

    Article  Google Scholar 

  17. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286–90

    PubMed  CAS  Google Scholar 

  18. Lowe JK, Brox L, Henderson JF. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res 1977 Mar; 37 (3): 736–43

    PubMed  CAS  Google Scholar 

  19. CellCept (mycophenolate mofetil) product information. June 1995, Hoffman-La Roche Inc., Nutley, NJ 07110–1199, USA

  20. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996 Apr; 28 (2): 925–9

    PubMed  CAS  Google Scholar 

  21. Wu JC. Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discovery Design 1994; 2: 185–204

    Article  CAS  Google Scholar 

  22. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995; 17 (6): 690–9

    Article  PubMed  CAS  Google Scholar 

  23. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995; 17 (6): 685–9

    Article  PubMed  CAS  Google Scholar 

  24. Parker G, Bullingham R, Kamm B, et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996 Apr; 36 (4): 332–41

    PubMed  CAS  Google Scholar 

  25. Zucker K, Esquenazi V, Rosen A, et al. Unexpected augmentation of MMF pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy, and analogous in vitro findings [abstract]. International Congress of the Transplantation Society; 1996 Aug 25–30; Barcelona, 60

  26. Eugui EM, Almquist S, Muller CD, et al. Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991 Feb; 33 (2): 161–73

    Article  PubMed  CAS  Google Scholar 

  27. Grailer A, Nichols J, Hullett D, et al. Inhibition of human B-cell responses in vitro by RS-61443, cyclosporine A, and DAB486IL-2. Transplant Proc 1991 Feb; 23 (1): 314–5

    PubMed  CAS  Google Scholar 

  28. Kimball JA, Pescovitz MD, Book BK, et al. Reduced human IgG anti-Atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995 Dec 27; 60 (12): 1379–83

    Article  PubMed  CAS  Google Scholar 

  29. Dayton JS, Turka LA, Thompson CB, et al. Comparison of the effects of mizoribine with those of azathioprine 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992 Apr; 41: 671–6

    PubMed  CAS  Google Scholar 

  30. Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. Transplant Proc 1990 Aug; 22: 1659–62

    PubMed  CAS  Google Scholar 

  31. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993 Nov–Dec; 12 (6 Pt 2): 275–86

    Google Scholar 

  32. Platz KP, Eckhoff DE, Bechstein WO, et al. RS-61443 for reversal of acute rejection in canine renal allografts. Surgery 1991 Oct; 110:736–41

    PubMed  CAS  Google Scholar 

  33. Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993 Feb; 25 (1 Pt 1): 754–5

    PubMed  CAS  Google Scholar 

  34. Langman LJ, Legatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid induced immunosuppres-sion in renal transplant recipients. Transplantation 1996 Sep 15; 62 (5): 666–72

    Article  PubMed  CAS  Google Scholar 

  35. Sollinger HW, Deierhoi MH, Beizer FO, et al. RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992 Feb; 53 (2): 428–32

    Article  PubMed  CAS  Google Scholar 

  36. Sollinger HW, Beizer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992 Oct; 216 (4): 513–9

    Article  PubMed  CAS  Google Scholar 

  37. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 May 27; 345: 1321–5

    Google Scholar 

  38. Gonwa TA. Mycophenolate mofetil for maintenance therapy in kidney transplantation. Clin Transplant 1996; 10: 128–30

    PubMed  CAS  Google Scholar 

  39. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renaltransplantation. Transplantation 1996 Apr 15; 61 (7): 1029–37

    Article  Google Scholar 

  40. Sollinger HW, U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995 Aug 15; 60 (3): 225–32

    Article  PubMed  CAS  Google Scholar 

  41. Sollinger HW, Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 1996 Dec; 28 (6) Suppl. 1: 24–9

    PubMed  CAS  Google Scholar 

  42. Cecka JM. Early rejection: determining the fate of renal transplants. Transplant Proc 1991 Feb; 23 (2 Pt 1): 1263–4

    PubMed  CAS  Google Scholar 

  43. Naimark DM, Cole E. Determinants of long term renal allograft survival. Transplant Rev 1994 Jul; 8 (3): 93

    Article  Google Scholar 

  44. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993 May; 55: 933–5

    Article  Google Scholar 

  45. Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996 Mar 15; 61 (5): 722–9

    Article  Google Scholar 

  46. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and non-human primate recipients of heart allografts. Transplant Proc 1991 Apr 23; Suppl. 2: 19–25

    PubMed  Google Scholar 

  47. Hullett DA, Kawamura T, Fujino Y, et al. Prolongation of allograft and xenograft survival with mycophenolate mofetil (RS-61443) and brequinar sodium (DUP-785). Transplant Proc 1993 Feb; 25 (1): 700–1

    PubMed  CAS  Google Scholar 

  48. Yatscoff RW, Wang S, Keenan R. Efficacy of rapamycin, RS-61443 and cyclophosphamide in the prolongation of survival of discordant pig-to-rabbit cardiac xenografts. Transplant Proc 1994 Jun; 26 (3): 1271–3

    PubMed  CAS  Google Scholar 

  49. Murase N, Starzl TE, Demetris AJ, et al. Hamster-to-rat heart and liver xenotransplantation with FK 506 plus antiproliferation drugs. Transplantation 1993 Apr; 55: 701–8

    Article  PubMed  CAS  Google Scholar 

  50. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart recipients. Transplantation 1993 Jul; 56 (1): 75–82

    Article  PubMed  CAS  Google Scholar 

  51. Kirklin J, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994 May–Jun; 13 (3): 444–50

    PubMed  CAS  Google Scholar 

  52. Renlund DG, Gopinathon SK, Kfoury AG, et al. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10: 136–9

    PubMed  CAS  Google Scholar 

  53. Bechstein WO, Schilling M, Steele DM, et al. RS-61443/ cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993 Feb; 25 Pt 1: 702–3

    PubMed  CAS  Google Scholar 

  54. Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993 Feb; 25: 697

    PubMed  CAS  Google Scholar 

  55. Freise CE, Hebert M, Osorio RW, et al. Maintenance immuno-suppression with prednisone and RS-61443 alone following liver transplant. Transplant Proc 1993 Apr; 25 (2): 1758–9

    PubMed  CAS  Google Scholar 

  56. Hebert M, Lake J, Linna TJ, et al. Mycophenolate mofetil for prophylaxis against rejection following orthotopic liver transplantation [abstract]. 15th World Congress of the Transplantation Society; 1994 Aug 28–Sep 2; Kyoto, 343

  57. Hao L, Lafferty AJ, Allison AC, et al. RS-61443 allows islet allografting and specific tolerance in adult mice. Transplant Proc 1990 Apr; 22: 876–9

    PubMed  CAS  Google Scholar 

  58. Qi S, Chen H, Xu D, et al. Prolongation of pancreas allograft survival by mycophenolate mofetil in the rat. Transplant Proc 1996 Apr; 28 (2): 932–3

    PubMed  CAS  Google Scholar 

  59. Stegall MD, Simon M, Wachs M, et al. Decreased rejection in simultaneous pancreas-kidney (SPK) transplantation with mycophenolate mofetil (MM): a randomized trial of tacrolimus and cyclosporine [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26–29; Dallas

  60. D’alessandro AM, Rankin M, McVey J, et al. Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine and prednisone. Transplantation 1993 Apr; 55 (4): 695–701

    Article  PubMed  Google Scholar 

  61. Lewis RL, Canafax DM, Pettit KG, et al. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Transplant Proc 1996 Aug; 28 (4): 2214–7

    PubMed  CAS  Google Scholar 

  62. Danovitch GM, editor. Handbook of kidney transplantation. New York: Little, Brown and Company, 1996

    Google Scholar 

  63. Louis-Touizer C, Nuijten MJ, Bayle F, et al. Economic contribution of mofetil mycophenolate as preventive immunosuppressive treatment after renal transplantation from cadaver. Presse Med 1996 Nov 2; 25 (33): 1577–82

    PubMed  CAS  Google Scholar 

  64. McEvoy GK, editor. American Hospital Formulary Service Drug Information. Bethesda: American Society of Health-System Pharmacists, 1997

    Google Scholar 

  65. Aroldi A, Tarantino A, Montagnino G, et al. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients. Transplantation 1997 Feb; 63 (3): 380–6

    Article  PubMed  CAS  Google Scholar 

  66. Cvetkovic M, Mann G, Romero D, et al. The deleterious effects of long-term cyclosporin A, cyclosporin G and FK506 on bone mineral metabolism in vivo. Transplantation 1994 Apr; 57 (8): 1231–7

    Article  PubMed  CAS  Google Scholar 

  67. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996; 42 (8B): 1316–21

    PubMed  CAS  Google Scholar 

  68. Steinmuller DR. Cyclosporine nephrotoxicity. Cleve Clin J Med 1989; 56: 89–95

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacy and Surgery, Division of Organ Transplantation, F6/133 Clinical Science Center, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin, 53792-7375, USA

    William D. Simmons, Stephen C. Rayhill & Hans W. Sollinger

Authors
  1. William D. Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen C. Rayhill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans W. Sollinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William D. Simmons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simmons, W.D., Rayhill, S.C. & Sollinger, H.W. Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant Rejection. Drug-Safety 17, 75–92 (1997). https://doi.org/10.2165/00002018-199717020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199717020-00001

Keywords

Search

Navigation